AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Feasibility and Safety of Early Mobilization and Rehabilitation in Intensive Care Unit Patients

Recruitingn/aAges 18 Years - anyAllClaudia Aristizábal
💬

In plain words

What the trial is, and whether it could suit you

Intensive Care Unit Acquired Weakness (ICU-AW) is a common complication of critical illnesses, occurring in approximately 50% of ICU patients and is strongly associated with increased morbidity, physical impairments, and both short- and long-term mortality. The main characteristics of ICU-AW are symmetrical generalised muscle weakness affecting both respiratory and limb muscles; however, the clinical phenotype may differ depending on age, disease burden, length of ICU stay, and mechanical ventilation duration. The objective of the present study is to evaluate the feasibility achieved and the safety outcomes reported in a cohort of critically ill patients who undergo early mobilisation and rehabilitation in intensive care units. This research is a multicentre prospective cohort study.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patients ≥ 18 years of age admitted to the intensive care units. Exclusion Criteria: * Patients requiring extracorporeal membrane oxygenation (ECMO). * Patients without indication for early mobilisation in the ICU (severe hemodynamic instability, acute brain or spinal injury with rest orders, anaemia (Hb \<8 mg/dl), thrombocytopenia (platelets \<50,000), active systemic inflammatory response according to institutional protocols). * Patients in the postoperative period of cardiac transplantation.
💊

What it tests

  • Early mobilization and rehabilitation
📍

Where

4 sites
Clínica Reina Sofia Pediátrica y Mujer
Bogotá, Colombia
Clinica Univesitaria Colombia
Bogotá, Colombia
Clínica Infantil Santa María del Lago
Bogotá, Colombia
Clínica Reina Sofia
Bogotá, Colombia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy